The USP <71> sterility testing sample size is one of the most closely scrutinized items in regulatory audits and inspections: how many units to pull from each batch and how much product to transfer into each culture medium are not laboratory choices but compendial requirements defined by two tables in the chapter. A sampling plan below the minimum makes the test non-compliant, with direct consequences for batch release. In this guide we look at how to apply the USP <71> sample size rules correctly, how they align with Ph. Eur. 2.6.1, and which mistakes to avoid to stay audit-ready.
USP <71> sample size: what the chapter requires
USP <71> Sterility Tests is a text harmonized across the three pharmacopeias of the Pharmacopeial Discussion Group (USP, Ph. Eur. and JP). The test uses two culture media: Fluid Thioglycollate Medium (FTM), incubated at 30–35 °C and intended primarily for anaerobic as well as aerobic bacteria, and Soybean–Casein Digest Medium (SCDM/TSB), incubated at 20–25 °C for fungi and aerobic bacteria. Incubation lasts not less than 14 days, with periodic observation of the cultures.
Sample size is governed by two distinct tables answering two different questions:
- Table 2 — how much product to take from each container for each medium, depending on fill volume or weight;
- Table 3 — how many units to test per batch, depending on batch size and product type.
The rules apply both to membrane filtration — to be preferred whenever the nature of the product permits — and to direct inoculation.
How many units to test per batch: Table 3
Table 3 sets the minimum number of articles to be tested in relation to the number of articles in the batch. The main thresholds for the most common categories are summarized below.
| Product type | Batch size | Minimum number of units to be tested |
|---|---|---|
| Parenteral preparations | ≤ 100 containers | 10% or 4 containers, whichever is greater |
| 101–500 containers | 10 containers | |
| > 500 containers | 2% or 20 containers, whichever is less | |
| Large-volume parenterals | — | 2% or 10 containers, whichever is less |
| Ophthalmic and other non-injectable preparations | ≤ 200 containers | 5% or 2 containers, whichever is greater |
| > 200 containers | 10 containers | |
| Bulk solid products | ≤ 4 containers | Each container |
| 5–50 containers | 20% or 4 containers, whichever is greater | |
| > 50 containers | 2% or 10 containers, whichever is greater |
A frequently misunderstood point: if the contents of each unit are sufficient for both media (per Table 2), they may be divided into equal portions added to each medium. If the contents are not sufficient for both, twice the number of units indicated in the table must be used.
Topics like this one — compendial requirements translated into operational practice — are the bread and butter of The Pragmatic GMP, GuideGxP's free weekly newsletter: one concrete, no-frills GMP analysis in your inbox every week. Subscribe here.
How much product for each medium: Table 2
Table 2 defines the minimum quantity to be used for each medium, for every sampled container. For liquids:
- volume < 1 mL: the whole contents of the container;
- 1–40 mL: half the contents, but not less than 1 mL;
- > 40 mL and ≤ 100 mL: 20 mL;
- > 100 mL: 10% of the contents, but not less than 20 mL;
- antibiotic liquids: 1 mL.
For solids:
- < 50 mg: the whole contents of the container;
- 50 mg to less than 300 mg: half the contents, but not less than 50 mg;
- 300 mg to 5 g: 150 mg;
- > 5 g: 500 mg.
For insoluble preparations, creams and ointments the reference quantity is at least 200 mg, while for medical devices the whole device is used, cut into pieces or disassembled.
USP <71> and Ph. Eur. 2.6.1: harmonization and interchangeability
The USP <71> sample size tables match those of chapter 2.6.1 of the European Pharmacopoeia and the corresponding chapter of the Japanese Pharmacopoeia: the text was harmonized by the Pharmacopeial Discussion Group. ICH guideline Q4B Annex 8, adopted by the authorities of the ICH regions (via EMA for the EU and FDA for the US), recognizes the interchangeability of the three chapters for regulatory purposes, with some local clarifications listed in the annex itself.
Two practical caveats, however. First: interchangeability does not exempt you from declaring in the dossier which pharmacopeia applies and from managing the residual divergences flagged by the authorities. Second: for aseptically manufactured sterile products, EU GMP Annex 1 requires sterility test samples to be representative of the whole batch and to include in particular the highest-risk units: those filled at the beginning and end of the aseptic fill and after significant line interventions. The compendial minimum of Table 3 must therefore be combined with a risk-based unit selection rationale.
Typical audit findings on sample size
- Sampling below the minimum for expensive products: the economic value of units (biologics, ATMPs, small batches) does not justify departures from Table 3; reductions apply only where the chapter itself provides for them (e.g. very small batches of bulk solids).
- Confusing the two tables: Table 3 counts containers per batch, Table 2 counts quantities per container and per medium; the sampling plan must document both.
- Forgetting to double the units when the contents of one container are not sufficient for both media.
- Non-representative selection: units all taken from the same point of the fill, without covering start, end and interventions, in conflict with Annex 1.
- Misaligned SOPs between the site and the contract laboratory: the contract lab applies one pharmacopeia while the dossier declares another.
GuideGxP recommendation
The most robust way to make your sample size defensible is to remove any ad-hoc calculation from sampling day: reproduce Tables 2 and 3 in the sterility test SOP, prepare a matrix for your site's recurring formats and batch sizes (with the number of units pre-calculated and verified by QA), and build the Annex 1 representativeness rationale into the sampling plan, with a map of the sampling points. In an audit, consistency between SOP, batch record and regulatory dossier is the first thing the inspector checks.
If you work across multiple markets and need to manage pharmacopeial divergences beyond the sterility test, the operational guide Pharmacopoeias Compared in GMP: Managing USP – Ph. Eur. – JP – BP Divergences in GxP Audits provides decision criteria and ready-to-use tools to defend your compendial choices in inspections.
